Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43845   clinical trials with a EudraCT protocol, of which   7282   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone for the Treatment of Major Depressive Disorder with Mixed Features

    Summary
    EudraCT number
    		 2012-004132-33
    Trial protocol
    		 GB  
    Global end of trial date
    01 Oct 2014

    Results information
    Results version number
    		 v1(current)
    This version publication date
    02 Sep 2016
    First version publication date
    02 Sep 2016
    Other versions

    Trial information

    		 Close Top of page
    Trial identification
    Sponsor protocol code
    D1050304
    Additional study identifiers
    ISRCTN number
    		 -
    US NCT number
    		 NCT01421134
    WHO universal trial number (UTN)
    		 -
    Sponsors
    Sponsor organisation name
    Sunovion Pharmaceuticals Inc.
    Sponsor organisation address
    One Bridge PlazaNorth, Suite 510, Fort Lee, United States, 07024
    Public contact
    Manager, Sunovion Pharmaceuticals Inc., 001 1-866-503-6351, clinicaltrialdisclosure@sunvion.com
    Scientific contact
    Director, Sunovion Pharmaceuticals Inc., 001 1-866-503-6351, clinicaltrialdisclosure@sunvion.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    01 Oct 2014
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    01 Oct 2014
    Global end of trial reached?
    Yes
    Global end of trial date
    01 Oct 2014
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with mixed features.This clinical study is designed to test how well Lurasidone works to treat major depressive disorder with mixed features.
    Protection of trial subjects
    This trial was conducted in accordance with the ethical principles of Good Clinical Practice, according to the ICH Harmonized Tripartite Guideline.
    Background therapy
    		 -
    Evidence for comparator
    		 -
    Actual start date of recruitment
    01 Sep 2011
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Russian Federation: 31
    Country: Number of subjects enrolled
    United States: 60
    Country: Number of subjects enrolled
    Ukraine: 62
    Country: Number of subjects enrolled
    United Kingdom: 4
    Country: Number of subjects enrolled
    Serbia: 52
    Worldwide total number of subjects
    209
    EEA total number of subjects
    4
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    203
    From 65 to 84 years
    6
    85 years and over
    0

    Subject disposition

    		 Close Top of page
    Recruitment
    Recruitment details
    		 A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study of lurasidone for the Treatment of Major Depressive Disorder with Mixed Features. This study enrolled subjects at 44 sites in 5 countries, enrollment started on 01Sept2011.

    Pre-assignment
    Screening details
    		 Subjects were evaluated for eligibility during a screening period of up to 14 days. Subjects were washed out from prior or concomitant medications, where applicable, prior to randomization.Treatment with prior psychotropic medications.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    		 Yes
    Allocation method
    Randomised - controlled
    Blinding used
    		 Double blind
    Roles blinded
    		 Subject, Investigator, Carer, Assessor

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    		 lurasidone
    Arm description
    		 lurasidone 20, 40 or 60 mg lurasidone: 20, 40, 60 mg, flexible dose, once daily PM 6 weeks
    Arm type
    		 Experimental

    Investigational medicinal product name
    lurasidone
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    once daily

    Arm title
    		 Placebo
    Arm description
    		 Placebo Placebo: Placebo
    Arm type
    		 Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    once daily

    Number of subjects in period 1
    		lurasidone Placebo
    Started
    109
    100
    Completed
    102
    85
    Not completed
    7
    15
         Consent withdrawn by subject
    1
    1
         Administrative
    -
    1
         Adverse event, non-fatal
    3
    5
         Lost to follow-up
    1
    1
         Lack of efficacy
    2
    4
         Protocol deviation
    -
    3

    Baseline characteristics

    		 Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    lurasidone
    Reporting group description
    		 lurasidone 20, 40 or 60 mg lurasidone: 20, 40, 60 mg, flexible dose, once daily PM 6 weeks

    Reporting group title
    Placebo
    Reporting group description
    		 Placebo Placebo: Placebo

    Reporting group values
    		 lurasidone Placebo Total
    Number of subjects
    		 109 100 209
    Age Categorical
    Units: participants
        <=18 years
    		 1 0 1
        Between 18 and 65 years
    		 106 96 202
        >=65 years
    		 2 4 6
    Age Continuous
    Units: years
        arithmetic mean (standard deviation)
    		 43.6 ( 12.08 ) 46.4 ( 12.01 ) -
    Gender, Male/Female
    Units: participants
        Female
    		 73 72 145
        Male
    		 36 28 64
    Race (NIH/OMB)
    Units: Subjects
        American Indian or Alaska Native
    		 0 0 0
        Asian
    		 0 1 1
        Native Hawaiian or Other Pacific Islander
    		 0 0 0
        Black or African American
    		 14 12 26
        White
    		 94 86 180
        More than one race
    		 0 0 0
        Unknown or Not Reported
    		 1 1 2
    Region of Enrollment
    Units: Subjects
        Russian Federation
    		 18 13 31
        United States
    		 34 26 60
        Ukraine
    		 30 32 62
        United Kingdom
    		 1 3 4
        Serbia
    		 26 26 52

    End points

    		 Close Top of page
    End points reporting groups
    Reporting group title
    lurasidone
    Reporting group description
    		 lurasidone 20, 40 or 60 mg lurasidone: 20, 40, 60 mg, flexible dose, once daily PM 6 weeks

    Reporting group title
    Placebo
    Reporting group description
    		 Placebo Placebo: Placebo

    Primary: Mean Change from baseline to the 6-week study endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) total scores

    		 Close Top of page
    End point title
    		 Mean Change from baseline to the 6-week study endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) total scores
    End point description
    The MADRS consists of 10 items, each rated on a Likert scale, from 0=”Normal” to 6=”Most Severe”. The MADRS total score is calculated as the sum of the 10 items. The MADRS total score ranges from 0 to 60. Higher scores are associated with greater severity.
    End point type
    Primary
    End point timeframe
    Baseline to Week 6
    End point values
    		 lurasidone Placebo
    Number of subjects analysed
    108
    100
    Units: units on a scale
        least squares mean (standard error)
    -20.5 ( 0.95 )
    -13 ( 1 )
    Statistical analysis title
    		 STATISTICAL_ANALYSIS_TITLE
    Comparison groups
    lurasidone v Placebo
    Number of subjects included in analysis
    208
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 < 0.0001
    Method
    		 Mixed models analysis
    Parameter type
    		 Least Square Mean Difference
    Point estimate
    -7.5
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -10.2
         upper limit
    		 -4.8
    Variability estimate
    Standard error of the mean
    Dispersion value
    1.37

    Secondary: Mean change from baseline to the 6-week study endpoint in the Clinical Global Impression-Severity of Illness (CGI-S) score

    		 Close Top of page
    End point title
    		 Mean change from baseline to the 6-week study endpoint in the Clinical Global Impression-Severity of Illness (CGI-S) score
    End point description
    The CGI-S score is a single value, clinician-rated assessment of illness severity and ranges from 1= ‘Normal, not at all ill’ to 7= ‘Among the most extremely ill patients’. A higher score is associated with greater illness severity.
    End point type
    Secondary
    End point timeframe
    Baseline to Week 6
    End point values
    		 lurasidone Placebo
    Number of subjects analysed
    108
    100
    Units: units on a scale
        least squares mean (standard error)
    -1.83 ( 0.109 )
    -1.18 ( 0.115 )
    Statistical analysis title
    		 STATISTICAL_ANALYSIS_TITLE
    Comparison groups
    lurasidone v Placebo
    Number of subjects included in analysis
    208
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 < 0.0001
    Method
    		 Mixed models analysis
    Parameter type
    		 Least Square Mean Difference
    Point estimate
    -0.65
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -0.96
         upper limit
    		 -0.34
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.157

    Secondary: Mean change from baseline to Week 6 in the Young Mania Rating Scale (YMRS) total score

    		 Close Top of page
    End point title
    		 Mean change from baseline to Week 6 in the Young Mania Rating Scale (YMRS) total score
    End point description
    The YMRS is an 11-item clinician-rated instrument used to assess the severity of mania. Seven items are rated on a 5-point scale, ranging from 0 to 4, and four items are rated on a 9-point scale, ranging from 0 to 8. The YMRS total score is calculated as the sum of the 11 individual items and ranges from 0 to 60. Higher scores are associated with greater severity of mania.
    End point type
    Secondary
    End point timeframe
    Baseline to Week 6
    End point values
    		 lurasidone Placebo
    Number of subjects analysed
    108
    100
    Units: units on a scale
        least squares mean (standard error)
    -7 ( 0.35 )
    -4.9 ( 0.37 )
    Statistical analysis title
    		 STATISTICAL_ANALYSIS_TITLE
    Statistical analysis description
    last observation carried forward (LOCF)
    Comparison groups
    lurasidone v Placebo
    Number of subjects included in analysis
    208
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 < 0.0001
    Method
    		 Mixed models analysis
    Parameter type
    		 Least Square Mean Difference
    Point estimate
    -2.1
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -3.1
         upper limit
    		 -1.1
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.5

    Secondary: Mean change from baseline to week 6 in the Sheehan Disability Scale (SDS) total score

    		 Close Top of page
    End point title
    		 Mean change from baseline to week 6 in the Sheehan Disability Scale (SDS) total score
    End point description
    The SDS is a composite of three self-rated items designed to measure the extent to which three major sectors (work/school, social life/leisure, and family life/home responsibility) in the patient’s life are impaired by depressive symptoms. These three items are responded to on a visual analogue scale (VAS) ranging through 0 (no impairment), 1–3 (mild), 4–6 (moderate), 7–9 (marked) and 10 (extreme) disability. The SDS total score is calculated as the sum of the three items and ranges from 0 (unimpaired) to 30 (highly impaired).
    End point type
    Secondary
    End point timeframe
    Baseline to Week 6
    End point values
    		 lurasidone Placebo
    Number of subjects analysed
    70
    69
    Units: units on a scale
        least squares mean (standard error)
    -11.2 ( 0.88 )
    -6.4 ( 0.88 )
    Statistical analysis title
    		 STATISTICAL_ANALYSIS_TITLE
    Comparison groups
    lurasidone v Placebo
    Number of subjects included in analysis
    139
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 = 0.0001
    Method
    		 ANCOVA
    Parameter type
    		 Least Square Mean Difference
    Point estimate
    -4.8
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -7.2
         upper limit
    		 -2.4
    Variability estimate
    Standard error of the mean
    Dispersion value
    1.21

    Secondary: Mean change from baseline to week 6 in the Hamilton Rating Scale for Anxiety(HAM-A) total score

    		 Close Top of page
    End point title
    		 Mean change from baseline to week 6 in the Hamilton Rating Scale for Anxiety(HAM-A) total score
    End point description
    The HAM-A is used to quantify the severity of anxiety symptomatology and consists of 14 items. Each item is rated on a 5-point scale, ranging from 0 (not present) to 4 (severe/disabling). The HAM-A total score is calculated as the sum of the 14 individual items and ranges from 0 to 56. Higher scores are associated with greater degree of anxiety.
    End point type
    Secondary
    End point timeframe
    Baseline to Week 6
    End point values
    		 lurasidone Placebo
    Number of subjects analysed
    105
    98
    Units: units on a scale
        least squares mean (standard error)
    -9.9 ( 0.58 )
    -5.4 ( 0.59 )
    Statistical analysis title
    		 STATISTICAL_ANALYSIS_TITLE
    Statistical analysis description
    last observation carried forward (LOCF)
    Comparison groups
    lurasidone v Placebo
    Number of subjects included in analysis
    203
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 < 0.0001
    Method
    		 ANCOVA
    Parameter type
    		 Least Square Mean Difference
    Point estimate
    -4.5
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 -6.1
         upper limit
    		 -2.9
    Variability estimate
    Standard error of the mean
    Dispersion value
    0.81

    Secondary: Percentage of subjects who achieve a response, defined as ≥ 50% reduction from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) total score at week 6 (LOCF).

    		 Close Top of page
    End point title
    		 Percentage of subjects who achieve a response, defined as ≥ 50% reduction from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) total score at week 6 (LOCF).
    End point description
    End point type
    Secondary
    End point timeframe
    Baseline to Week 6
    End point values
    		 lurasidone Placebo
    Number of subjects analysed
    108
    100
    Units: percentage of subjects
        number (not applicable)
    64.8
    30
    Statistical analysis title
    		 STATISTICAL_ANALYSIS_TITLE
    Comparison groups
    lurasidone v Placebo
    Number of subjects included in analysis
    208
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 < 0.0001
    Method
    		 Regression, Logistic
    Parameter type
    		 Odds ratio (OR)
    Point estimate
    6.615
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 3.251
         upper limit
    		 13.459

    Secondary: Percentage of subjects who achieve a remission, defined as a Montgomery-Asberg Depression Rating Scale (MADRS) total score of ≤ 12 at Week 6 (LOCF)

    		 Close Top of page
    End point title
    		 Percentage of subjects who achieve a remission, defined as a Montgomery-Asberg Depression Rating Scale (MADRS) total score of ≤ 12 at Week 6 (LOCF)
    End point description
    End point type
    Secondary
    End point timeframe
    Baseline to Week 6
    End point values
    		 lurasidone Placebo
    Number of subjects analysed
    108
    100
    Units: percentage of subjects
        number (not applicable)
    49.1
    23
    Statistical analysis title
    		 STATISTICAL_ANALYSIS_TITLE
    Comparison groups
    lurasidone v Placebo
    Number of subjects included in analysis
    208
    Analysis specification
    Pre-specified
    Analysis type
    		 superiority
    P-value
    		 < 0.0001
    Method
    		 Regression, Logistic
    Parameter type
    		 Odds ratio (OR)
    Point estimate
    4.27
    Confidence interval
         level
    		 95%
         sides
    2-sided
         lower limit
    		 2.105
         upper limit
    		 8.663

    Adverse events

    		 Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    6 Weeks
    Assessment type
    		 Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    		 MedDRA
    Dictionary version
    14.0
    Reporting groups
    Reporting group title
    Placebo
    Reporting group description
    		 Placebo Placebo: Placebo

    Reporting group title
    Lurasidone
    Reporting group description
    		 Lurasidone 20, 40 or 60 mg Lurasidone: 20, 40, 60 mg, flexible dose, once daily PM 6 weeks

    Serious adverse events
    		 Placebo Lurasidone
    Total subjects affected by serious adverse events
         subjects affected / exposed
    0 / 100 (0.00%)
    1 / 109 (0.92%)
         number of deaths (all causes)
    0
    0
         number of deaths resulting from adverse events
    0
    0
    Psychiatric disorders
    Depression Suicidal
         subjects affected / exposed
    0 / 100 (0.00%)
    1 / 109 (0.92%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 2%
    Non-serious adverse events
    		 Placebo Lurasidone
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    29 / 100 (29.00%)
    31 / 109 (28.44%)
    Injury, poisoning and procedural complications
    Contusion
         subjects affected / exposed
    2 / 100 (2.00%)
    0 / 109 (0.00%)
         occurrences all number
    2
    0
    Nervous system disorders
    Headache
         subjects affected / exposed
    6 / 100 (6.00%)
    6 / 109 (5.50%)
         occurrences all number
    7
    6
    Somnoelence
         subjects affected / exposed
    1 / 100 (1.00%)
    5 / 109 (4.59%)
         occurrences all number
    1
    6
    Akathisia
         subjects affected / exposed
    2 / 100 (2.00%)
    4 / 109 (3.67%)
         occurrences all number
    2
    4
    Dizziness
         subjects affected / exposed
    3 / 100 (3.00%)
    4 / 109 (3.67%)
         occurrences all number
    3
    5
    Gastrointestinal disorders
    Nausea
         subjects affected / exposed
    2 / 100 (2.00%)
    7 / 109 (6.42%)
         occurrences all number
    2
    7
    Abdominal discomfort
         subjects affected / exposed
    1 / 100 (1.00%)
    4 / 109 (3.67%)
         occurrences all number
    1
    5
    Dry mouth
         subjects affected / exposed
    1 / 100 (1.00%)
    3 / 109 (2.75%)
         occurrences all number
    1
    3
    Skin and subcutaneous tissue disorders
    Pruritus
         subjects affected / exposed
    2 / 100 (2.00%)
    1 / 109 (0.92%)
         occurrences all number
    2
    1
    Psychiatric disorders
    Insomnia
         subjects affected / exposed
    11 / 100 (11.00%)
    6 / 109 (5.50%)
         occurrences all number
    11
    7
    Anxiety
         subjects affected / exposed
    9 / 100 (9.00%)
    4 / 109 (3.67%)
         occurrences all number
    12
    4
    Renal and urinary disorders
    Haemarturia
         subjects affected / exposed
    2 / 100 (2.00%)
    0 / 109 (0.00%)
         occurrences all number
    2
    0
    Infections and infestations
    Urinary Tract Infection
         subjects affected / exposed
    2 / 100 (2.00%)
    1 / 109 (0.92%)
         occurrences all number
    3
    1

    More information

    		 Close Top of page

    Substantial protocol amendments (globally)
    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)
    Were there any global interruptions to the trial? No

    Limitations and caveats
    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 19 08:38:40 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA